STING1 and colorectal cancer: For example, a prodrug STING agonist (GB2) targeting TREM2+ TAMs promoted a shift toward an inflammatory M1 phenotype, increased phagocytic activity, and enhanced CD8+ T cell infiltration, ultimately leading to complete tumor regression in murine colorectal cancer models without systemic toxicity [108].